Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.41 |
| ▸ | CALML3 | P27482 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393630 | 0.84 | CALML3 (0.59) | CALML3MAOALMNAF10 | |
| SCHEMBL21555918 | 0.81 | MAOA (0.39) | CALML3MAOALMNAF10 | |
| SCHEMBL21555920 | 0.81 | MAOA (0.40) | ROCK2CALML3MAOALMNAF10 | |
| SCHEMBL21555917 | 0.81 | MAOA (0.38) | CALML3MAOALMNAF10 | |
| SCHEMBL11983279 | 0.81 | CALML3 (0.59) | CALML3MAOALMNAF10 | |
| SCHEMBL10259164 | 0.81 | CALML3 (0.59) | CALML3MAOALMNAF10 | |
| SCHEMBL21555906 | 0.81 | MAOA (0.40) | CALML3MAOAHDAC1LMNA | |
| SCHEMBL18403006 | 0.80 | ATM (0.39) | CALML3MAOAALDH1A1LMNAF10 | |
| SCHEMBL21555919 | 0.79 | MAOA (0.41) | CALML3MAOALMNAF10 | |
| SCHEMBL18403016 | 0.79 | MAOA (0.39) | CALML3MAOALMNAF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | L3MBTL1 4859/4885ROCK2 2494/4885CALML3 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.